Thrivent Financial for Lutherans
PTCT icon

Thrivent Financial for Lutherans’s PTC Therapeutics PTCT Stock Holding History

Thrivent Financial for Lutherans’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.44M Buy
54,470
+880
+2% +$63.5K 0.01% 1055
2026
Q1 		$3.65M Sell
53,590
-1,579
-3% -$112K 0.01% 1055
2025
Q4 		$4.19M Buy
+55,169
New +$4.01M 0.01% 1023
2025
Q1 		– Sell
-20,339
Closed -$919K – 2505
2024
Q4 		$919K Sell
20,339
-18,759
-48% -$803K ﹤0.01% 1952
2024
Q3 		$1.45M Buy
+39,098
New +$1.31M ﹤0.01% 1671
2024
Q2 		– Sell
-33,852
Closed -$985K – 2574
2024
Q1 		$985K Hold
33,852
– – ﹤0.01% 1905
2023
Q4 		$933K Buy
+33,852
New +$774K ﹤0.01% 1884

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Thrivent Financial for Lutherans's PTCT Position: Q2 2026 in Review

Thrivent Financial for Lutherans increased its PTC Therapeutics (PTCT) stake by 1.6% in Q2 2026, buying an estimated $63.5K and bringing the position to 54,470 shares worth $4.44M. The position accounts for 0.01% of the portfolio, ranked #1055.

Thrivent Financial for Lutherans first reported a position in PTCT in Q4 2023 and has held it in 7 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Thrivent Financial for Lutherans held 54,470 shares of PTC Therapeutics worth $4.44M as of Q2 2026.
  • Thrivent Financial for Lutherans bought 880 PTC Therapeutics shares in Q2 2026, an estimated $63.5K.
  • PTC Therapeutics made up 0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #1055 holding.
  • Thrivent Financial for Lutherans first reported a position in PTC Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.